Literature DB >> 1846615

von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation.

P J Fay1, J V Coumans, F J Walker.   

Abstract

Factor VIII, a cofactor of the intrinsic clotting pathway, is proteolytically inactivated by the vitamin K-dependent serine protease, activated protein C in a reaction requiring Ca2+ and a phospholipid surface. Factor VIII was inactivated 15 times faster than factor VIII in complex with either von Willebrand factor (vWf) or the large homodimeric fragment, SPIII (vWf residues 1-1365). Free factor VIII or factor VIII in complex with a smaller fragment, SPIII-T4 (vWf residues 1-272), were inactivated at the same rate, suggesting that this effect was dependent upon the size of factor VIII-vWf complex rather than changes in factor VIII brought about by occupancy of the vWf-binding site. Thrombin cleavage of the factor VIII light chain to remove the vWf-binding site eliminated the protective effects of vWf. In the absence of phospholipid, high levels of the protease inactivated both free and vWf-bound factor VIII at equivalent rates. Using the same conditions, isolated heavy chains and the heavy chains of factor VIII were proteolyzed at similar rates. Taken together, these results suggested that, in the absence of phospholipid, inactivation of factor VIII is independent of factor VIII light chain and further suggest that vWf did not mask susceptible cleavage sites in the cofactor. Solution studies employing fluorescence energy transfer using coumarin-labeled factor VIII (fluorescence donor) and synthetic phospholipid vesicles labeled with octadecyl rhodamine (fluorescence acceptor) indicated saturable binding and equivalent extents of donor fluorescence quenching for factor VIII alone or when complexed with SPIII-T4. However, complexing of factor VIII with either vWf or SPIII eliminated its binding to the phospholipid. Since a phospholipid surface is required for efficient catalysis by the protease, these results suggest that vWf protects factor VIII by inhibiting cofactor-phospholipid interactions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846615

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.

Authors:  S W Pipe; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

3.  A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy.

Authors:  Alessandra Casonato; Viviana Daidone; Giovanni Barbon; Elena Pontara; Irene Di Pasquale; Lisa Gallinaro; Letizia Marullo; Giorgio Bertorelle
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

4.  Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry.

Authors:  J Spaargaren; P L Giesen; M P Janssen; J Voorberg; G M Willems; J A van Mourik
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

5.  Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.

Authors:  Puneet Gaitonde; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  Eur J Pharm Sci       Date:  2014-10-20       Impact factor: 4.384

6.  Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras.

Authors:  T C Nichols; C M Samama; D A Bellinger; J Roussi; R L Reddick; M Bonneau; M S Read; O Bailliart; G G Koch; M Vaiman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Trp2313-His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding.

Authors:  Zhuo Liu; Lin Lin; Cai Yuan; Gerry A F Nicolaes; Liqing Chen; Edward J Meehan; Bruce Furie; Barbara Furie; Mingdong Huang
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

8.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

9.  Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.

Authors:  Nadine Vollack-Hesse; Olga Oleshko; Sonja Werwitzke; Barbara Solecka-Witulska; Christoph Kannicht; Andreas Tiede
Journal:  Blood       Date:  2021-02-25       Impact factor: 22.113

10.  Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.

Authors:  Masahiro Takeyama; Keiji Nogami; Ryohei Kobayashi; Kenichi Ogiwara; Akira Taniguchi; Yasuaki Nakanishi; Yusuke Inagaki; Yasuhito Tanaka; Midori Shima
Journal:  Int J Hematol       Date:  2018-01-30       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.